Merck Sharp & Dohme: EPOCH Study

What is the EPOCH Study?

A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer’s Disease (Protocol No. MK-8931-017-10) (Also Known as SCH 900931, P07738)

Purpose: The clinical trial will assess the efficacy and safety of Verubecestat (MK-8931) compared to placebo during 78 week for Alzheimer’s Disease (AD). Participants may choose to participate in a long term double-blind extension phase for up an additional 260 weeks. Your participation in this study is completely voluntary.